Role of COX-2 in MCD Diet Induced Fibrosis and Its Corelation with PPARα

doi:10.3969/j.issn.1000-1565.2008.04.018

Abstract

CLC Number:

Q786

WANG Shi-yan,GAO Xiang-dong,LI Bao-qin,JIA Yan-hong. Role of COX-2 in MCD Diet Induced Fibrosis and Its Corelation with PPARα[J]. Journal of Hebei University (Natural Science Edition), 2008, 28(4): 414-422.

References

[1] Day, CP, James, OF. Steatohepatitis: a tale of two hits? (editorial) [J]. Gastroenterology 1998, 4(4).
[2] FARRELL G C, LARTER C Z. Nonalcoholic fatty liver disease:from steatosis to cirrhosis [J]. Hepatology 2006, 43(z1).
[3] HOTAMISLIGIL G S. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes [J]. Diabetes 2005, 54(z2).
[4] Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw Boris A, Poli G, Olefsky J, Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. [J]. Nature medicine 2005, 2(2).
[5] Ramadori G, Christ B. Cytokines and the hepatic acute-phase response. [J]. Seminars in liver disease 1999, 2(2).
[6] YU J, IP E, DELA PE(N)A A. COX-2 induction in mice with experimental nutritional steatohepatitis:Role as pro-inflammatory mediator [J]. Hepatology 2006, 43(04).
[7] CHENG A S, CHAN H L, LEUNG W K. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma:implication of HBx in upregulation of COX-2 [J]. Modern Pathology 2004, 17(10).
[8] Chi Man Tang T, Tung Ping Poon R, Fan ST. The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma. [J]. Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie 2005, Suppl.2(Suppl.2).
[9] NANJI A A, ZAKIM D, RAHEMTULLA A. Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat [J]. Hepatology 1997, 26(06).
[10] YAMAMOTO H, KONDO M, NAKAMORI S. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis [J]. Gastroenterology 2003, 125(02).
[11] Planaguma, A, Claria, J, Miquel, R, Lopez-Parra, M, Titos, E, Masferrer, JL, Arroyo, V, Rodes, J. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPAR gamma activation [J]. The FASEB Journal 2005, 7(7).
[12] SHINOZUKA H, LOMBARDI B, SELL S, IAMARINO RM. Early histological and functional alterations of ethionine liver carcinogenesis in rats fed a choline-deficient diet [J]. Cancer Research 1978, 38(04).
[13] Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? [J]. Journal of Internal Medicine 2007, 2(2).
[14] Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). [J]. The Journal of biological chemistry 1998, 10(10).
[15] Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. [J]. Hepatology 2003, 1(1).
[16] IP E, FARRELL G, HALL P. Administration of the potent PPARalpha agonist, Wy-14, 643, reverses nutritional fibrosis and steatohepatitis in mice [J]. Hepatology 2004, 39(05).
[17] McMahon RF. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. [J]. Journal of Clinical Pathology 2004, 4(4).
[18] NANJI A A, MIAO L, THOMAS P. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat [J]. GASTROENTEROLOGY 1997, 112(03).
[19] DINCHUK J E, CAR B D, FOCHT R J. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase Ⅱ [J]. Nature 1995, 378(6555).
[20] YU J, HUI A Y, CHU E S. Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis [J]. Gut 2007, 56(07).
[21] Miller C, Zhang M, He Y, Zhao J, Pelletier JP, Martel-Pelletier J, Di-Battista JA. Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: co-stimulation of AP-1 and CRE nuclear binding proteins. [J]. Journal of Cellular Biochemistry 1998, 4(4).
[22] Delerive P, De Bosscher-K, Besnard S, Vanden Berghe-W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. [J]. The Journal of biological chemistry 1999, 45(45).
[23] Grau R, Punzon C, Fresno M, Iniguez MA. Peroxisome-proliferator-activated receptor ot agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1 [J]. The Biochemical Journal 2006, 1(1).
[24] Suleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. [J]. Pharmacological reports: PR 2007, 3(3).
[25] Lehmann JM., Oliver BB., Ringold GM., Kliewer SA., Lenhard JM.. PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS ALPHA AND GAMMA ARE ACTIVATED BY INDOMETHACIN AND OTHER NON-STEROIDAL ANTI-INFLAMMATORY DRUGS [J]. The Journal of biological chemistry 1997, 6(6).
[26] Sheldrick EL, Derecka K, Marshall E, Chin EC, Hodges L, Wathes DC, Abayasekara DR, Flint AP. Peroxisome-proliferator-activated receptors and the control of levels of prostaglandin-endoperoxide synthase 2 by arachidonic acid in the bovine uterus. [J]. The Biochemical Journal 2007, 1(1).